Literature DB >> 16752394

Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40.

Samir Kumar-Singh1, Jessie Theuns, Bianca Van Broeck, Daniel Pirici, Krist'l Vennekens, Ellen Corsmit, Marc Cruts, Bart Dermaut, Rong Wang, Christine Van Broeckhoven.   

Abstract

The varied ways in which mutations in presenilins (PSEN1 and PSEN2) affect amyloid b precursor protein (APP) processing in causing early-onset familial Alzheimer disease (FAD) are complex and not yet properly understood. Nonetheless, one useful diagnostic marker is an increased ratio of Ab42 to Ab40 (Ab42/Ab40) in patients' brain and biological fluids as well as in transgenic mice and cells. We studied Ab and APP processing for a set of nine clinical PSEN mutations on a novel and highly reproducible enzyme-linked immunosorbent assay (ELISA)-based in vitro method and also sought correlation with brain Ab analyzed by image densitometry and mass spectrometry. All mutations significantly increased Ab42/Ab40 in vitro by significantly decreasing Ab40 with accumulation of APP C-terminal fragments, a sign of decreased PSEN activity. A significant increase in absolute levels of Ab42 was observed for only half of the mutations tested. We also showed that age-of-onset of PSEN1-linked FAD correlated inversely with Ab42/Ab40 (r = -0.89; P = 0.001) and absolute levels of Ab42 (r = -0.83; P = 0.006), but directly with Ab40 levels (r = 0.69; P = 0.035). These changes also partly correlated with brain Ab42 and Ab40 levels. Together, our data suggested that Ab40 might be protective by perhaps sequestering the more toxic Ab42 and facilitating its clearance. Also, the in vitro method we describe here is a valid tool for assaying the pathogenic potential of clinical PSEN mutations in a molecular diagnostic setting.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16752394     DOI: 10.1002/humu.20336

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  123 in total

1.  Amyloid precursor protein and tau transgenic models of Alzheimer's disease: insights from the past and directions for the future.

Authors:  Naruhiko Sahara; Jada Lewis
Journal:  Future Neurol       Date:  2010-05-01

Review 2.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

3.  Nicastrin is required for amyloid precursor protein (APP) but not Notch processing, while anterior pharynx-defective 1 is dispensable for processing of both APP and Notch.

Authors:  Chen Hu; Linlin Zeng; Ting Li; Michael A Meyer; Mei-Zhen Cui; Xuemin Xu
Journal:  J Neurochem       Date:  2016-01-17       Impact factor: 5.372

4.  Seeded strain-like transmission of β-amyloid morphotypes in APP transgenic mice.

Authors:  Götz Heilbronner; Yvonne S Eisele; Franziska Langer; Stephan A Kaeser; Renata Novotny; Amudha Nagarathinam; Andreas Aslund; Per Hammarström; K Peter R Nilsson; Mathias Jucker
Journal:  EMBO Rep       Date:  2013-09-03       Impact factor: 8.807

5.  Amyloid β peptides promote autophagy-dependent differentiation of mouse neural stem cells: Aβ-mediated neural differentiation.

Authors:  Maria B Fonseca; Susana Solá; Joana M Xavier; Pedro A Dionísio; Cecília M P Rodrigues
Journal:  Mol Neurobiol       Date:  2013-06-02       Impact factor: 5.590

Review 6.  Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases.

Authors:  G Brent Irvine; Omar M El-Agnaf; Ganesh M Shankar; Dominic M Walsh
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

Review 7.  Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Authors:  Harald Hampel; Yong Shen; Dominic M Walsh; Paul Aisen; Les M Shaw; Henrik Zetterberg; John Q Trojanowski; Kaj Blennow
Journal:  Exp Neurol       Date:  2009-10-06       Impact factor: 5.330

8.  Modulation of gamma-secretase specificity using small molecule allosteric inhibitors.

Authors:  Christopher C Shelton; Lei Zhu; Deming Chau; Li Yang; Rong Wang; Hakim Djaballah; Hui Zheng; Yue-Ming Li
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-11       Impact factor: 11.205

Review 9.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics.

Authors:  Eric Karran; Marc Mercken; Bart De Strooper
Journal:  Nat Rev Drug Discov       Date:  2011-08-19       Impact factor: 84.694

Review 10.  Development and mechanism of γ-secretase modulators for Alzheimer's disease.

Authors:  Christina J Crump; Douglas S Johnson; Yue-Ming Li
Journal:  Biochemistry       Date:  2013-05-02       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.